Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 29;39(4):e22.
doi: 10.3346/jkms.2024.39.e22.

The Epidemiology of Hepatitis B Virus Infection in Korea: 15-Year Analysis

Log Young Kim #  1 , Jeong-Ju Yoo #  2 , Young Chang  3 , Hoongil Jo  4 , Young Youn Cho  5 , Sangheun Lee  6 , Dong Hyeon Lee  7 , Jae Young Jang  8 ; Korean Association for the Study of the Liver
Affiliations

The Epidemiology of Hepatitis B Virus Infection in Korea: 15-Year Analysis

Log Young Kim et al. J Korean Med Sci. .

Abstract

Background: The purpose of this study is to investigate the epidemiological changes in chronic hepatitis B (CHB) and assess the impact of coronavirus disease 2019 (COVID-19) over the past 15 years in a region endemic to hepatitis B virus (HBV).

Methods: National Health Insurance Service claims data of hepatitis B patients spanning from 2007 to 2021 was utilized. To compare the characteristics of the hepatitis B group, a control group adjusted for age and gender through propensity score matching analysis was established.

Results: The number of patients with CHB has consistently increased over the past 15 years. The average age of the CHB patient group has shown a yearly rise, while the prevalence of male dominance has gradually diminished. The proportions of hepatocellular carcinoma, liver cirrhosis, and decompensation have exhibited a declining pattern, whereas the proportion of liver transplants has continuously risen. Patients with CHB have demonstrated significantly higher medical and medication costs compared to the control group. Moreover, patients with CHB have shown a higher prevalence of comorbidities along with a significantly higher rate of concomitant medication usage. During the COVID period, the HBV group experienced a substantial decrease in the number of outpatient visits and overall medical costs compared to the control group.

Conclusion: The epidemiology of CHB has undergone significant changes over the past 15 years, encompassing shifts in prevalence, severity, medical costs, and comorbidities. Furthermore, the impact of COVID-19 has been observed to decrease healthcare utilization among patients with CHB when compared to controls.

Keywords: COVID-19 Infection; Epidemiology; HBV.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Healthcare resource utilization: total medical costs (A) and number of visits to medical institutions (B).
HBV = hepatitis B virus.
Fig. 2
Fig. 2. Hepatitis B patient visits to medical institutions by residential area. (A) Number of patients by urban and rural areas, (B) concentration of medical care by region.
Fig. 3
Fig. 3. Subgroup analysis: total number (A) and proportion of patients (B) by liver disease severity.
HCC = hepatocellular carcinoma, CHB = chronic hepatitis B.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(2):434. - PMC - PubMed
    1. Broquetas T, Carrión JA. Current perspectives on nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B virus. Hepat Med. 2022;14:87–100. - PMC - PubMed
    1. Les I, García-Martínez R, Córdoba J, Quintana M, Esteban R, Buti M. Current trends in chronic hepatitis B management: results of a questionnaire. Eur J Gastroenterol Hepatol. 2009;21(10):1177–1183. - PubMed
    1. Perrillo RP, Marcellin P. Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. Antivir Ther. 2010;15(1):13–22. - PubMed
    1. Liu LZ, Sun J, Hou J, Chan HL. Improvements in the management of chronic hepatitis B virus infection. Expert Rev Gastroenterol Hepatol. 2018;12(11):1153–1166. - PubMed